cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Arbutus Biopharma Corporation
34 own
65 watching
Current Price
$2.9
$-0.05
(-1.69%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
442.86M
52-Week High
52-Week High
3.64
52-Week Low
52-Week Low
1.85
Average Volume
Average Volume
0.71M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization442.86M
icon52-Week High3.64
icon52-Week Low1.85
iconAverage Volume0.71M
iconDividend Yield--
iconP/E Ratio--
What does the Arbutus Biopharma Corporation do?
Arbutus Biopharma Corporation, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of chronic hepatitis B (HBV) infections in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). Its lead candidate is ARB-1467, a multi-component RNAi therapeutic product that is designed for the elimination of HBV surface antigen expression in patients chronically infected with HBV. Its HBV product candidates also comprise ARB-1740, a RNAi HBV candidate that is in preclinical studies; small molecule cccDNA formation inhibitors for reducing the amount of cccDNA in the infected liver cell; HBV core protein assembly inhibitors; ARB-1598, a toll-like receptor; surface antigen secretion inhibitors; cccDNA epigenetic modifiers; stimulator of interferon genes agonists; and cyclophilin inhibitor drug candidates, including OCB-030 and other cyclophilin inhibitors. In addition, it develops TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials for the treatment of gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and hepatocellular carcinoma; TKM-HTG, a multi-component RNAi therapeutic that targets a combination of genes expressed in the liver, which play a role in triglyceride metabolism; and TKM-ALDH, an aldehyde dehydrogenase to induce long term acute sensitivity to ethanol to treat severe alcohol use disorder. Further, its partnered programs consists of ALN-TTR02,whichis in Phase III clinical study, a therapeutic targeting transthyretin mediated amyloidosis; ALN-VSP for liver cancer; ALN-PCS02 for hypercholesterolemia; Marqibo for treating Philadelphia chromosome-negative acute lymphoblastic leukemia; and DCR-PH1 for primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.
Read More
How much money does Arbutus Biopharma Corporation make?
News & Events about Arbutus Biopharma Corporation.
Globe Newswire
9days ago
WARMINSTER, Pa., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that Tram Tran, MD has notified ...
Globe Newswire
1month ago
Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into Phase 1 clinical trials in 2023 Strong financial position; cash runway into Q4 2024 WARMINSTER, Pa., ...
Ticker Report
2 months ago
Arbutus Biopharma (NASDAQ:ABUS Get Rating) had its price target reduced by HC Wainwright from $7.50 to $6.00 in a research report report published on Thursday morning, The Fly reports. They currently have a buy rating on the biopharmaceutical companys stock. Separately, StockNews.com ...
Globe Newswire
2 months ago
Financially strong with a projected cash runway into thesecond quarter of 2024 HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729, our RNAi therapeutic, and NA therapy On-track to achieve multiple additional milestones before year ...
Globe Newswire
4 months ago
WARMINSTER, Pa., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that Gaston Picchio, PhD, Chief ...
Frequently Asked Questions
Frequently Asked Questions
What is Arbutus Biopharma Corporation share price today?
plus_minus_icon
Can Indians buy Arbutus Biopharma Corporation shares?
plus_minus_icon
How can I buy Arbutus Biopharma Corporation shares from India?
plus_minus_icon
Can Fractional shares of Arbutus Biopharma Corporation be purchased?
plus_minus_icon
What are the documents required to start investing in Arbutus Biopharma Corporation stocks?
plus_minus_icon
What is today’s traded volume of Arbutus Biopharma Corporation?
plus_minus_icon
What is today’s market capitalisation of Arbutus Biopharma Corporation?
plus_minus_icon
What is the 52-Week High and Low Range of Arbutus Biopharma Corporation?
plus_minus_icon
What percentage is Arbutus Biopharma Corporation down from its 52-Week High?
plus_minus_icon
What percentage is Arbutus Biopharma Corporation up from its 52-Week Low?
plus_minus_icon
Current Price
$2.9
$-0.05
(-1.69%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$3.15
$0.30 (10.53 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$6.53
$-0.12 (-1.88 %)
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.
$2.23
$-0.04 (-1.76 %)
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc.
$1.83
$-0.14 (-7.11 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$3.15
$0.30 (10.53 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$6.53
$-0.12 (-1.88 %)
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.
$2.23
$-0.04 (-1.76 %)
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc.
$1.83
$-0.14 (-7.11 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00